lscros.blogg.se - Statins and grapefruit warnings

#Statins and grapefruit warnings trial#
#Statins and grapefruit warnings plus#

Oral Contraceptives: Values for norethindrone and ethinyl estradiol may be increased ( 7.3).

Rifampin should be simultaneously co-administered with LIPITOR ( 7.2).

Caution should be used when prescribing with LIPITOR ( 7).

Other Lipid-Lowering Medications: Use with fibrate products or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects.

#Statins and grapefruit warnings plus#

Lopinavir plus ritonavir, simeprevir, fibric acid derivatives, erythromycin, azole antifungals, lipid-modifying doses of niacin, colchicineĬonsider the risk/benefit of concomitant use with atorvastatin placebo ( 5.6).ĭrug Interactions that may Increase the Risk of Myopathy and Rhabdomyolysis with LIPITOR ( 2.6, 5.1, 7.1, 12.3) Interacting AgentsĬyclosporine, tipranavir plus ritonavir, glecaprevir plus pibrentasvirĬlarithromycin, itraconazole, saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir, elbasvir plus grazoprevir, letermovir

A higher incidence of hemorrhagic stroke was seen in patients without CHD but with stroke or TIA within the previous 6 months in the LIPITOR 80 mg group vs.

Check liver enzyme tests before initiating therapy and as clinically indicated thereafter ( 5.3).

Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur.

IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment positive anti-HMG CoA reductase antibody muscle biopsy showing necrotizing myopathy and improvement with immunosuppressive agents ( 5.2).

Immune-Mediated Necrotizing Myopathy (IMNM): There have been rare reports of IMNM, an autoimmune myopathy, associated with statin use.

LIPITOR therapy should be discontinued if myopathy is diagnosed or suspected ( 2.6, 5.1, 8.5). Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness.

Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported. Predisposing factors include advanced age (> 65), uncontrolled hypothyroidism, and renal impairment. Myopathy and Rhabdomyolysis: Risks increase when higher doses are used concomitantly with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, human immunodeficiency virus (HIV) or hepatitis C virus (HCV) protease inhibitors).LIPITOR has not been studied in Fredrickson Types I and V dyslipidemias ( 1.3).

#Statins and grapefruit warnings trial#

Reduce elevated total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) after failing an adequate trial of diet therapy ( 1.2).Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) ( 1.2).Reduce elevated TG in adult patients with hypertriglyceridemia and primary dysbetalipoproteinemia ( 1.2).Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( 1.2).Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in adult patients with CHD ( 1.1).

Reduce the risk of MI and stroke in adult patients with type 2 diabetes without CHD, but with multiple risk factors ( 1.1).

Reduce the risk of MI, stroke, revascularization procedures, and angina in adult patients without CHD, but with multiple risk factors ( 1.1).LIPITOR is an HMG-CoA reductase inhibitor indicated as an adjunct therapy to diet to: